Medtronic gains FDA OK for heart resynchronization device

05/7/2013 | Bloomberg Businessweek

The FDA has granted Medtronic approval to market its Viva system, an implantable device used to treat heart failure by resynchronizing the beating of a patient's heart. Patients who received the device saw 21% reduced hospitalizations during the first year of implantation compared with those using traditional systems, a company official said.

View Full Article in:

Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI